 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
15 December 1994 | Volume 121 Issue 12 | Pages 905-911
Objective: To determine the antimicrobial activity and tolerability of clarithromycin for treating bacteremic Mycobacterium avium complex disease in patients with the acquired immunodeficiency syndrome (AIDS).
Design: A randomized, double-blind, dose-ranging study.
Setting: Outpatient clinics.
Patients: 154 patients with human immunodeficiency virus (HIV) infection and blood cultures positive for M. avium complex who had symptomatic disease.
Interventions: Random assignment to clarithromycin at dosages of 500 mg, 1000 mg, or 2000 mg twice daily for 12 weeks.
Main Outcome Measure: Median number of colony-forming units of M. avium complex per milliliter of blood.
Results: Clarithromycin decreased mycobacterial CFUs from 2.7 to 2.8 log 10/mL of blood at baseline to less than 0 log 10/mL during follow-up (P < 0.0001). After 2 weeks, patients receiving 500 mg twice daily were less likely to be culture negative than were patients receiving 1000 or 2000 mg twice daily (11% compared with 33% or 29%; P = 0.08). At 6 weeks, the median number of CFUs of M. avium complex/mL of blood was 0 or 1 for all three groups. Clarithromycin-resistant isolates of M. avium complex developed in 46% of patients at a median of 16 weeks. Median survival was longer in patients assigned to 500 mg twice daily (median, 249 days) than in patients assigned to 1000 mg or 2000 mg. Death in the first 12 weeks was lowest in the 500-mg group (P = 0.007).
Conclusions: Clarithromycin therapy acutely decreased M. avium complex bacteremia in patients with HIV infection by more than 99%. Clarithromycin, 500 mg twice daily, was well tolerated and associated with better survival. Emergence of clarithromycin-resistant organisms was an important problem.
Author and Article Information
From the Johns Hopkins University School of Medicine, Baltimore, Maryland; Rush Medical College, Chicago, Illinois; University of Southern California-Los Angeles County Medical Center, Los Angeles, California; National Jewish Center for Immunology and Respiratory Medicine, Denver, Colorado; Abbott Laboratories, Abbott Park, Illinois; the National Institute of Allergy and Infectious Diseases, Bethesda, Maryland; BioPharm, Inc., Philadelphia, Pennsylvania.
ARTICLE
Clarithromycin Therapy for Bacteremic Mycobacterium avium Complex Disease
A Randomized, Double-Blind, Dose-ranging Study in Patients with AIDS
For members of the AIDS Clinical Trials Study Team, see the Appendix.
Requests for Reprints: Richard E. Chaisson, MD, AIDS Service, The Johns Hopkins University, 600 North Wolfe Street, Carnegie 292, Baltimore, MD 21287-6220.
Grant Support: By grant 5M01RR00722 and the AIDS Clinical Trials Group.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  P A Jenkins, I A Campbell, J Banks, C M Gelder, R J Prescott, and A P Smith Clarithromycin vs ciprofloxacin as adjuncts to rifampicin and ethambutol in treating opportunist mycobacterial lung diseases and an assessment of Mycobacterium vaccae immunotherapy Thorax, July 1, 2008; 63(7): 627 - 634. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E. Bermudez, N. Motamedi, C. Chee, G. Baimukanova, P. Kolonoski, C. Inderlied, P. Aralar, G. Wang, L. T. Phan, and L. S. Young EDP-420, a Bicyclolide (Bridged Bicyclic Macrolide), Is Active against Mycobacterium avium Antimicrob. Agents Chemother., May 1, 2007; 51(5): 1666 - 1670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Griffith, T. Aksamit, B. A. Brown-Elliott, A. Catanzaro, C. Daley, F. Gordin, S. M. Holland, R. Horsburgh, G. Huitt, M. F. Iademarco, et al. An Official ATS/IDSA Statement: Diagnosis, Treatment, and Prevention of Nontuberculous Mycobacterial Diseases Am. J. Respir. Crit. Care Med., February 15, 2007; 175(4): 367 - 416. [Full Text] [PDF]
|
|
|
|
|
|
D. E. Griffith, B. A. Brown-Elliott, B. Langsjoen, Y. Zhang, X. Pan, W. Girard, K. Nelson, J. Caccitolo, J. Alvarez, S. Shepherd, et al. Clinical and Molecular Analysis of Macrolide Resistance in Mycobacterium avium Complex Lung Disease Am. J. Respir. Crit. Care Med., October 15, 2006; 174(8): 928 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. A. J. M. Bakker-Woudenberg, W. van Vianen, D. van Soolingen, H. A. Verbrugh, and M. A. van Agtmael Antimycobacterial Agents Differ with Respect to Their Bacteriostatic versus Bactericidal Activities in Relation to Time of Exposure, Mycobacterial Growth Phase, and Their Use in Combination Antimicrob. Agents Chemother., June 1, 2005; 49(6): 2387 - 2398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. R. Fleming Surrogate Endpoints And FDA's Accelerated Approval Process Health Aff., January 1, 2005; 24(1): 67 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Koga, T. Fukuoka, N. Doi, T. Harasaki, H. Inoue, H. Hotoda, M. Kakuta, Y. Muramatsu, N. Yamamura, M. Hoshi, et al. Activity of capuramycin analogues against Mycobacterium tuberculosis, Mycobacterium avium and Mycobacterium intracellulare in vitro and in vivo J. Antimicrob. Chemother., October 1, 2004; 54(4): 755 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Bermudez, P. Kolonoski, L. E. Seitz, M. Petrofsky, R. Reynolds, M. Wu, and L. S. Young SRI-286, a Thiosemicarbazole, in Combination with Mefloquine and Moxifloxacin for Treatment of Murine Mycobacterium avium Complex Disease Antimicrob. Agents Chemother., September 1, 2004; 48(9): 3556 - 3558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. K. Field, D. Fisher, and R. L. Cowie Mycobacterium avium complex Pulmonary Disease in Patients Without HIV Infection Chest, August 1, 2004; 126(2): 566 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Bermudez, R. Reynolds, P. Kolonoski, P. Aralar, C. B. Inderlied, and L. S. Young Thiosemicarbazole (Thiacetazone-Like) Compound with Activity against Mycobacterium avium in Mice Antimicrob. Agents Chemother., August 1, 2003; 47(8): 2685 - 2687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Woods, N. Williams-Bouyer, R. J. Wallace Jr., B. A. Brown-Elliott, F. G. Witebsky, P. S. Conville, M. Plaunt, G. Hall, P. Aralar, and C. Inderlied Multisite Reproducibility of Results Obtained by Two Broth Dilution Methods for Susceptibility Testing of Mycobacterium avium Complex J. Clin. Microbiol., February 1, 2003; 41(2): 627 - 631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. b. H. Masur, J. E. Kaplan, and K. K. Holmes Guidelines for Preventing Opportunistic Infections among HIV-Infected Persons--2002: Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America Ann Intern Med, September 3, 2002; 137(5_Part_2): 435 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Chacon, Z. Feng, N. B. Harris, N. E. Caceres, L. G. Adams, and R. G. Barletta Mycobacterium smegmatisD-Alanine Racemase Mutants Are Not Dependent on D-Alanine for Growth Antimicrob. Agents Chemother., January 1, 2002; 46(1): 47 - 54. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. E. Bermudez, C. B. Inderlied, P. Kolonoski, M. Wu, P. Aralar, and L. S. Young Telithromycin Is Active against Mycobacterium avium in Mice despite Lacking Significant Activity in Standard In Vitro and Macrophage Assays and Is Associated with Low Frequency of Resistance during Treatment Antimicrob. Agents Chemother., August 1, 2001; 45(8): 2210 - 2214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Research Committee of the British Thoracic Society First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol Thorax, March 1, 2001; 56(3): 167 - 172. [Abstract] [Full Text]
|
|
|
|
|
|
L. E. Bermudez, C. B. Inderlied, P. Kolonoski, M. Petrofsky, P. Aralar, M. Wu, and L. S. Young Activity of Moxifloxacin by Itself and in Combination with Ethambutol, Rifabutin, and Azithromycin In Vitro and In Vivo against Mycobacterium avium Antimicrob. Agents Chemother., January 1, 2001; 45(1): 217 - 222. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. D. Purdy Management and Prevention of Opportunistic Infections in the HIV-Infected Patient Journal of Pharmacy Practice, December 1, 2000; 13(6): 475 - 498. [Abstract] [PDF]
|
|
|
|
|
|
L. E. Bermudez, K. Nash, M. Petrofsky, L. S. Young, and C. B. Inderlied Clarithromycin-Resistant Mycobacterium avium Is Still Susceptible to Treatment with Clarithromycin and Is Virulent in Mice Antimicrob. Agents Chemother., October 1, 2000; 44(10): 2619 - 2622. [Abstract] [Full Text]
|
|
|
|
|
|
Subcommittee of the Joint Tuberculosis Committee o Management of opportunist mycobacterial infections: Joint Tuberculosis Committee guidelines 1999 Thorax, March 1, 2000; 55(3): 210 - 218. [Full Text]
|
|
|
|
|
|
USPHS/IDSA Prevention of Opportunistic Infections 1999 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections in Persons Infected with Human Immunodeficiency Virus Ann Intern Med, December 7, 1999; 131(11): 873 - 908. [Full Text] [PDF]
|
|
|
|
|
|
S. L. Koletar, A. J. Berry, M. H. Cynamon, J. Jacobson, J. S. Currier, R. R. MacGregor, M. W. Dunne, and D. J. Williams Azithromycin as Treatment for Disseminated Mycobacterium avium Complex in AIDS Patients Antimicrob. Agents Chemother., December 1, 1999; 43(12): 2869 - 2872. [Abstract] [Full Text]
|
|
|
|
|
|
L. E. Bermudez, P. Kolonoski, M. Wu, P. A. Aralar, C. B. Inderlied, and L. S. Young Mefloquine Is Active In Vitro and In Vivo against Mycobacterium avium Complex Antimicrob. Agents Chemother., August 1, 1999; 43(8): 1870 - 1874. [Abstract] [Full Text]
|
|
|
|
|
|
L. Steele-Moore, K. Stark, and W. J. Holloway In Vitro Activities of Clarithromycin and Azithromycin against Clinical Isolates of Mycobacterium avium-M. intracellulare Antimicrob. Agents Chemother., June 1, 1999; 43(6): 1530 - 1530. [Full Text] [PDF]
|
|
|
|
 |
|
 K.-H. Khoo, E. Jarboe, A. Barker, J. Torrelles, C.-W. Kuo, and D. Chatterjee Altered Expression Profile of the Surface Glycopeptidolipids in Drug-resistant Clinical Isolates of Mycobacterium avium Complex J. Biol. Chem., April 2, 1999; 274(14): 9778 - 9785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Portaels, H. Traore, K. De Ridder, and W. M. Meyers In Vitro Susceptibility of Mycobacterium ulcerans to Clarithromycin Antimicrob. Agents Chemother., August 1, 1998; 42(8): 2070 - 2073. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. G. Nelson, D. E. Griffith, B. A. Brown, and R. J. Wallace Jr Results of operation in Mycobacterium avium-intracellulare lung disease Ann. Thorac. Surg., August 1, 1998; 66(2): 325 - 330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. J. O'Brien and A. A. Vernon New Tuberculosis Drug Development . How Can We Do Better? Am. J. Respir. Crit. Care Med., June 1, 1998; 157(6): 1705 - 1707. [Full Text] [PDF]
|
|
|
|
|
|
R. Hafner, J. Bethel, M. Power, B. Landry, M. Banach, L. Mole, H. C. Standiford, S. Follansbee, P. Kumar, R. Raasch, et al. Tolerance and Pharmacokinetic Interactions of Rifabutin and Clarithromycin in Human Immunodeficiency Virus-Infected Volunteers Antimicrob. Agents Chemother., March 1, 1998; 42(3): 631 - 639. [Abstract] [Full Text]
|
|
|
|
|
|
L. E. Bermudez, M. Petrofsky, P. Kolonoski, and L. S. Young Emergence of Mycobacterium avium Populations Resistant to Macrolides during Experimental Chemotherapy Antimicrob. Agents Chemother., January 1, 1998; 42(1): 180 - 183. [Abstract] [Full Text]
|
|
|
|
|
|
Diagnosis and Treatment of Disease Caused by Nontuberculous Mycobacteria Am. J. Respir. Crit. Care Med., July 1, 1997; 156(2): 1 - 25. [Full Text]
|
|
|
|
 |
|
 S. D. Shafran, J. Singer, D. P. Zarowny, P. Phillips, I. Salit, S. L. Walmsley, I. W. Fong, M. J. Gill, A. R. Rachlis, R. G. Lalonde, et al. A Comparison of Two Regimens for the Treatment of Mycobacterium avium Complex Bacteremia in AIDS: Rifabutin, Ethambutol, and Clarithromycin versus Rifampin, Ethambutol, Clofazimine, and Ciprofloxacin N. Engl. J. Med., August 8, 1996; 335(6): 377 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pierce, S. Crampton, D. Henry, L. Heifets, A. LaMarca, M. Montecalvo, G. P. Wormser, H. Jablonowski, J. Jemsek, M. Cynamon, et al. A Randomized Trial of Clarithromycin as Prophylaxis against Disseminated Mycobacterium avium Complex Infection in Patients with Advanced Acquired Immunodeficiency Syndrome N. Engl. J. Med., August 8, 1996; 335(6): 384 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. V. Havlir, M. P. Dube, F. R. Sattler, D. N. Forthal, C. A. Kemper, M. W. Dunne, D. M. Parenti, J. P. Lavelle, A. C. White, M. D. Witt, et al. Prophylaxis against Disseminated Mycobacterium avium Complex with Weekly Azithromycin, Daily Rifabutin, or Both N. Engl. J. Med., August 8, 1996; 335(6): 392 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. R. Horsburgh Advances in the Prevention and Treatment of Mycobacterium avium Disease N. Engl. J. Med., August 8, 1996; 335(6): 428 - 430. [Full Text]
|
|
|
|
 |
|
 The Potency of Clarithromycin against MAC AIDS Clinical Care, February 1, 1995; 1995(201): 6 - 6. [Full Text]
|
|
|
|
 |
|
 CLARITHROMYCIN FOR M. AVIUM COMPLEX Journal Watch (General), December 30, 1994; 1994(1230): 5 - 5. [Full Text]
|
|
Article
